QuidelOrtho Corporation (QDEL)

QuidelOrtho's adjusted EPS of $0.13, up about 8% from $0.12 a year earlier, topped the -$0.05 estimate by about 366% in the fiscal second quarter of 2026, reported August 6 on preliminary results, while revenue rose about 3% to about $630.9 million with gross margin near 43%. Labs remained the largest segment at about $353.1 million, down about 5%, while Point of Care fell 34% to about $112.8 million and Donor Screening dropped 39% to about $7.8 million. Gross profit came in at about $272.9 million, net income improved 64% to negative about $92.9 million from negative $255.4 million a year ago, and operating cash flow was negative $110.6 million.